Cullinan Therapeutics (CGEM) Stock Price Target 2026

The average analyst price target for Cullinan Therapeutics is $30.25, 155.9% above the current price. Of 10 analysts, 10 rate it Buy. Targets range from $19 to $42. The latest change came on Oct 28, 2026, when BTIG raised its price target on Cullinan Therapeutics from $40 to $41 and kept a Buy rating.

The Average Analyst Price Target for Cullinan Therapeutics is $30.25.

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

10Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$30.25Upside to Avg. PT+155.9%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Cullinan Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	BTIG	Julian Harrison	PT Raise	Buy	$40→$41
Oct 19, 2026	BTIG	Julian Harrison	Maintained	Buy	$40
Oct 2, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$35
Sep 25, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$30→$35
Sep 25, 2026	BTIG	Julian Harrison	Maintained	Buy	$40
Sep 14, 2026	BTIG	Julian Harrison	PT Raise	Buy	$39→$40
Aug 17, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$30
Aug 13, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$39→$42
Jul 29, 2026	BTIG	Julian Harrison	PT Raise	Buy	$38→$39
Jun 11, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$37
Jun 8, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$30
May 19, 2026	BTIG	Julian Harrison	Maintained	Buy	$38
May 8, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$36→$37
May 4, 2026	BTIG	Julian Harrison	Maintained	Buy	$38
Apr 28, 2026	BTIG	Julian Harrison	Maintained	Buy	$38
Apr 28, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$27→$30
Mar 11, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$34→$36
Feb 17, 2026	Citigroup	Samantha Semenkow	Initiate	Buy	$33
Feb 2, 2026	Guggenheim	Brad Canino	Initiate	Buy	$30
Jan 8, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$26→$27